Recent News

• 09.02.2025 - Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
• 09.02.2025 - Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
• 08.21.2025 - Trinity Biotech Appoints Paul Tivnan as Non-Executive Director
• 08.20.2025 - Regulatory Approval Granted for Commencement Of Trinity Biotech’s Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation
• 08.20.2025 - Regulatory Approval Granted for Commencement of Trinity Biotech’s Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation
• 08.15.2025 - Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service
• 08.14.2025 - Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service
• 08.12.2025 - Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor
• 08.12.2025 - Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor

Recent Filings

• 09.02.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.02.2025 - EX-99.1 EX-99.1
• 08.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.20.2025 - EX-99.1 EX-99.1
• 08.15.2025 - EX-99.1 EX-99.1
• 08.15.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.12.2025 - EX-99.1 EX-99.1
• 08.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.12.2025 - EX-99.1 EX-99.1
• 08.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]